Fulgent Genetics Inc.
17.17
-0.77 (-4.29%)
At close: Jan 14, 2025, 3:59 PM
17.13
-0.23%
After-hours Jan 14, 2025, 04:00 PM EST
undefined%
Bid 16.99
Market Cap 525.18M
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -5.52
PE Ratio (ttm) -3.11
Forward PE n/a
Analyst Hold
Ask 18.1
Volume 292,791
Avg. Volume (20D) 246,313
Open 18.04
Previous Close 17.94
Day's Range 16.88 - 18.04
52-Week Range 16.56 - 27.56
Beta undefined

About FLGT

Fulgent Genetics, Inc., together with its subsidiaries, provides COVID-19, molecular diagnostic, and genetic testing services to physicians and patients in the United States and internationally. The company offers genetic tests comprising Focus and Comprehensive oncology panels tests; Beacon carrier screening panels test for inherited conditions; solid tumor molecular profiling for somatic cancer testing; rapid whole genome testing for children i...

Sector Healthcare
IPO Date Sep 29, 2016
Employees 1,184
Stock Exchange NASDAQ
Ticker Symbol FLGT

Analyst Forecast

According to 1 analyst ratings, the average rating for FLGT stock is "Hold." The 12-month stock price forecast is $22, which is an increase of 28.13% from the latest price.

Buy 0.00%
Hold 100.00%
Sell 0.00%
Stock Forecasts

Next Earnings Release

Fulgent Genetics Inc. is scheduled to release its earnings on Feb 26, 2025, before market opens.
Analysts project revenue of $75.39M, reflecting a 6.93% YoY growth and earnings per share of -0.37, making a -232.14% decrease YoY.
10 months ago · Source
-8.12%
Fulgent Genetics shares are trading lower after th... Unlock content with Pro Subscription